Pharming PHAR
NASDAQ PHAR
$11.20 +0.60 (+5.66%)
At close: Oct 23, 2026 · 4:00 PM EDT

Pharming (PHAR) Sale and Maturity of Investments (2023 - 2026)

Updated

Analysis

Pharming (PHAR) Sale and Maturity of Investments (2023 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Investments Sold (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn -
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn 308.00 Mn
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn -
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn 1.30 Bn
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn 136.00 Mn
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn -
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn -
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn 1.03 Bn
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn 2.12 Bn
10 Pharming 785.88 Mn -8.48 Mn 141.47 Mn 18.12 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 18.12 Mn
Dec 31, 2025 11,000.00
Jun 30, 2025 84.97 Mn
Dec 31, 2024 -262.35 Mn
Sep 30, 2024 114.50 Mn
Jun 30, 2024 147.84 Mn
Dec 31, 2023 -86.45 Mn
API Access

Pharming Sale and Maturity of Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=sale-and-maturity-of-investments&ticker=PHAR&period=max&api_key=YOUR_API_KEY